Affiliation: University of California
- Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovirBrookie M Best
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093 0719, USA
J Acquir Immune Defic Syndr 59:376-81. 2012..The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF)...
- Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in childrenBrookie M Best
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093 0719, USA
J Acquir Immune Defic Syndr 58:385-91. 2011..In clinical practice, Kaletra tablets are occasionally crushed for pediatric administration. This study compared lopinavir/ritonavir exposure between whole and crushed tablets in HIV-infected children...
- Lopinavir tablet pharmacokinetics with an increased dose during pregnancyBrookie M Best
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA
J Acquir Immune Defic Syndr 54:381-8. 2010..This study determined lopinavir exposure with an increased dose of the new tablet formulation during the third trimester...
- Low atazanavir concentrations in cerebrospinal fluidBrookie M Best
Skaggs School of Pharmacy andPharmaceutical Sciences, School of Medicine, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, MC 0719, La Jolla, CA 92093 0719, USA
AIDS 23:83-7. 2009..The objective of this study was to determine atazanavir penetration into cerebrospinal fluid (CSF)...
- Tipranavir: a protease inhibitor for multi-drug resistant HIV-1Brookie Best
University of California, San Diego, CA 92103 8214, USA
Expert Opin Investig Drugs 15:59-70. 2006..It displays activity against the virus that is cross-resistant to other protease inhibitors. In this review, issues in treating multi-drug resistant HIV-1 and the potential clinical utility of tipranavir in the US will be discussed...
- Efavirenz--still first-line king?Brookie M Best
University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093 0719, USA
Expert Opin Drug Metab Toxicol 4:965-72. 2008..Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available...
- A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patientsBrookie M Best
University of California, San Diego, San Diego, CA 92013, USA
J Acquir Immune Defic Syndr 46:433-42. 2007..To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations...
- Impact of pregnancy on abacavir pharmacokineticsBrookie M Best
University of California San Diego, California 92103 8214, USA
AIDS 20:553-60. 2006..To describe abacavir pharmacokinetics during pregnancy and postpartum; physiological changes during pregnancy are known to affect antiretroviral drug disposition...
- Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre
University of California, San Diego, 150 W Washington St, San Diego, CA 92103, USA
Arch Neurol 65:65-70. 2008..To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lower cerebrospinal fluid (CSF) viral load...
- Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Miguel Goicoechea
University California, School of Medicine, San Diego, CA 92103, USA
Expert Opin Pharmacother 8:371-82. 2007....
- Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapyMiguel Goicoechea
Antiviral Research Center, University of California, San Diego, 150 W Washington St, Ste 100, San Diego, CA 92103, USA
J Infect Dis 197:102-8. 2008....
- Reduced lopinavir exposure during pregnancyAlice M Stek
Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
AIDS 20:1931-9. 2006..Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy...
- Lopinavir protein binding in HIV-1-infected pregnant womenF T Aweeka
Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
HIV Med 11:232-8. 2010..We report lopinavir (LPV) PB during third trimester (antepartum, AP) compared to > or =1.7 weeks postpartum (PP) to determine if FU changes compensate for reduced total concentrations reported previously...
- The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous systemScott L Letendre
University of California, 150 W Washington St, San Diego, CA 92103, USA
J Neuroimmune Pharmacol 2:120-7. 2007..Some of these drugs, such as serotonin reuptake inhibitors (SRIs) and HMG-CoA reductase inhibitors (statins), may do so by reducing HIV replication in the CNS and are already widely used by HIV-infected individuals...
- Lopinavir exposure with an increased dose during pregnancyMark Mirochnick
Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
J Acquir Immune Defic Syndr 49:485-91. 2008..The goal of this study was to determine LPV exposure during the third trimester of pregnancy and 2 weeks postpartum with a higher LPV/RTV dose...
- Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiariesJan D Hirsch
University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9500 Gilman Drive, Mail Code 0714, La Jolla, CA 92093 0714, USA
J Manag Care Pharm 15:32-41. 2009..In January 2005, a pilot program to evaluate MTM services for patients with HIV/AIDS began in California, allowing 10 HIV/AIDS specialty pharmacies to receive compensation for the MTM services that they provided to HIV/AIDS patients...
- Enhancing an introductory Pharmacy Practice Experience at free medical clinicsCandis M Morello
University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla 92093 0719, USA
Int J Pharm Pract 18:51-7. 2010..The aim of the study was to assess and improve first-year student pharmacists' satisfaction and learning experience in a Student-Run Free Medical Clinic Project (SFMCP) providing medical care to an underserved population...
- Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1David Croteau
HIV Neurobehavioral Research Center, University of California San Diego, 220 Dickinson, Suite B, 8208, San Diego, CA 92103, USA
Antimicrob Agents Chemother 54:5156-60. 2010..As a component of effective antiretroviral regimens or as the main antiretroviral, RAL likely contributes to the control of HIV replication in the nervous system...
- Development of an ambulatory palliative care pharmacist practiceRabia Samady Atayee
Doris A Howell Palliative Care ServiceUniversity of California, San DiegoSkaggs School of Pharmacy and Pharmaceutical Sciences, Jolla, CA 92093 0845, USA
J Palliat Med 11:1077-82. 2008..Our objective was to establish a model for incorporating an outpatient clinical pharmacist as part of a multidisciplinary palliative care team...
- Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depressionMiguel Goicoechea
University California San Diego, School of Medicine, San Diego, California 92103, USA
AIDS Patient Care STDS 20:233-7. 2006..It should be recognized that not all patients are capable of achieving lifelong medication adherence and may benefit from continued supervised therapy...
- Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki diseaseJane C Burns
Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital San Diego, La Jolla, CA, USA
J Pediatr 153:833-8. 2008..To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD)...